EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads

Naiara Larreina Vicente, Alessandra Lodrini, Esmee Groeneveld, Oya Tagit iD, Marie-José Goumans, Mangala Srinivas iD

ACS Biomaterials Science & Engineering · 09.11.2026 · 12 (11) · 6175-6189

DOI: 10.1021/acsbiomaterials.6c00915 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, online erschienen am 25.10.2026. Verfasst von Naiara Larreina Vicente und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology and Immunology (CBI), Wageningen University & Research (WUR), De Elst 1, Wageningen6708WD, The Netherlands. Hauptthemen laut MEDLINE: Polylactic Acid-Polyglycolic Acid Copolymer, Nanoparticles, Drug Carriers, Polyglycolic Acid. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 LEIT Nanotechnologies, HORIZON EUROPE Health, HORIZON EUROPE European Innovation Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two perfluorocarbon (PFC)-loaded PLGA nanoparticles (NPs) of different architectures were previously established as 19F MRI tracers: sodium cholate (NaCh)-stabilized core–shell particles (CSPs) and PVA-stabilized multicore particles (MCPs). Differing in their stabilizers and internal PFC distribution, they exhibited significant differences in stiffness, permeability, cell uptake, and biological behavior, with MCPs showing dramatically faster in vivo fluorine clearance, addressing an important barrier to the clinical translation of PFCs. Here, we explore the incorporation of rapamycin, a small hydrophobic drug, as a third immiscible phase to develop a theranostic platform for cardiac regeneration. By comparing the drug-loaded particle systems (Rapa-MCPs and Rapa-CSPs) against drug-free and PFC-free (Rapa-PLGA NPs) controls, we study how PFC presence and stabilizer-governed NP architectures affect multipayload incorporation, release, and biological behavior. PFC presence was associated with enhanced drug loading but faster release. A higher drug-to-polymer ratio increased loading but constrained PFC encapsulation above 2 wt %. NP architecture governed multipayload incorporation trade-offs: Rapa-CSPs showed preferential stabilization of the PFC phase over the drug and dye, and unpredictable drug release, reflecting greater sensitivity to multipayload incorporation; Rapa-MCPs could more flexibly accommodate multiple immiscible payloads at the expense of robust PFC stabilization, and showed a fast but gradual release. In vitro, encapsulated rapamycin retained mTOR-inhibitory activity, and Rapa-MCPs reduced TGF-β-driven fibrotic signaling in human living myocardial slices, supporting their therapeutic potential. These findings indicate that the stabilizers and resulting particle architectures govern payload partitioning and release in mutually immiscible multiphasic systems and provide practical design guidelines for structurally tunable polymer nanocarriers for 19F MRI-guided drug delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polylactic Acid-Polyglycolic Acid CopolymerNanoparticlesDrug CarriersPolyglycolic AcidFluorine-19 Magnetic Resonance ImagingSirolimusFluorocarbonsHumansLactic AcidDrug LiberationMagnetic Resonance ImagingAnimals

Stichwörter der Autor:innen

controlled releaseimage-guided drug deliverymultiphasic systemsparticle architectureperfluorocarbonspolymer nanoparticlestheranostics

Substanzen

Polylactic Acid-Polyglycolic Acid CopolymerSirolimusDrug CarriersFluorocarbonsPolyglycolic AcidLactic Acid

Autor:innen und Institutionen

  • Department of Cell Biology and Immunology (CBI), Wageningen University & Research (WUR), De Elst 1, Wageningen6708WD, The Netherlands.
  • Department of Cell and Chemical Biology (CCB), Leiden University Medical Center (LUMC), Einthovenweg 20, Leiden2333 ZC, The Netherlands.
  • Group of Biointerfaces, Institute for Chemistry and Bioanalytics, FHNW University of Applied Sciences and Arts Northwestern Switzerland, Hofackerstrasse 30, Muttenz4132, Switzerland.

ORCID-Profile: Oya Tagit, Mangala Srinivas

Förderung

  • H2020 LEIT Nanotechnologies
  • HORIZON EUROPE Health
  • HORIZON EUROPE European Innovation Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Hartstichting
  • H2020 Marie Sklodowska-Curie Actions

Zitieren

APA

Larreina Vicente, N., Lodrini, A., Groeneveld, E., Tagit, O., Goumans, M. J., & Srinivas, M. (2026). 19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads. ACS Biomaterials Science & Engineering, 12(11), 6175-6189. https://doi.org/10.1021/acsbiomaterials.6c00915

Vancouver

Larreina Vicente N, Lodrini A, Groeneveld E, Tagit O, Goumans MJ, Srinivas M. 19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads. ACS Biomaterials Science & Engineering. 2026;12(11):6175-6189. doi:10.1021/acsbiomaterials.6c00915

BibTeX
@article{LarreinaVicente2026,
  author = {Larreina Vicente, Naiara and Lodrini, Alessandra and Groeneveld, Esmee and Tagit, Oya and Goumans, Marie-José and Srinivas, Mangala},
  title = {19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads},
  journal = {ACS Biomaterials Science & Engineering},
  year = {2026},
  volume = {12},
  number = {11},
  pages = {6175--6189},
  doi = {10.1021/acsbiomaterials.6c00915}
}
Kostenlos starten →